|  |
| |
| Figure 1. Amino acid sequence of the human s100A1 monomer. Residues involved in binding Ca2+ are shown with downward arrows. Elements of secondary structure are indicated. |
| |
Description | S100A1 is a member of the S100 family of Ca2+-binding proteins. S100A1 exists as a dimer of two identical monomers. Each monomer contains 94 amino acids (figure 1), has a molecular weight of 10546 Da, and contains two EF-hand Ca2+-binding domains (Wright et al., 2005). The non-canonical amino terminal EF-hand contains 14 amino acids and is characteristic of S100 proteins. The carboxy terminal canonical EF-hand contains 12 amino acids and is characteristic of all S100/calmodulin/troponin superfamily members. Like other members of this superfamily, S100A1 possesses no inherent enzymatic activity and exerts its biological effects by interacting with and modulating the activity of target proteins (Zimmer et al., 2003). S100A1 undergoes an ~90 degree rotation of helix 3 upon binding calcium (figure 2), exposing a hydrophobic pocket that serves as the binding site for intracellular and extracellular proteins targets (Landar et al., 1998; Wright et al., 2009b; Zimmer and Weber, 2010). The amino acid sequence linking the two EF-hands confers family member-specific binding for some target proteins (Zimmer and Weber, 2010). |
|  |
| |
| Figure 2. The conformational change of the S100A1 dimer. Upon binding Ca2+, alpha-helix 3 (blue) undergoes an ~90 degree rotation, exposing a hydrophobic binding site that can interact with a variety of biological targets. Here, a peptide derived from ryanodine receptor (RyRPep; red) is shown binding to S100A1 (Wright et al., 2008). |
| |
Expression | S100 proteins are expressed exclusively in higher chordates in a cell-type and tissue-specific manner (Zimmer et al., 1995; Zimmer et al., 2005). It is the unique complement of S100 family members expressed in individual cells that allows cells to transduce changes in calcium levels into unique biological responses. While there are species-specific differences in S100A1 levels, all species exhibit intermediate to high levels of S100A1 in heart, skeletal muscle, smooth muscle, skin, brain, adipose and kidney (Kato et al., 1986; Zimmer and Van Eldik, 1987; Zimmer et al., 1991; Zimmer et al., 1995; Zimmer et al., 2005; Song and Zimmer, 1996; Kiewitz et al., 2000). Lung, liver, spleen, intestine, testis, thyroid gland, salivary gland, pancreas, ovary, placenta and prostate also contain detectable levels of S100A1 protein/mRNA. |
Localisation | In non-muscle cells, S100A1 is located in the perinuclear cytoplasm. In muscle cells, S100A1 co-localizes with the sarcolemma, sarcoplasmic reticulum and mitochondria. Extracellular forms of S100A1 have also been detected (Most et al., 2003; Hernández-Ochoa et al., 2009). |
Function | Like other S100 proteins, S100A1 has been implicated in a variety of biological and cellular processes. S100A1 mediates the suppression of chondrocyte differentiation (Saito et al., 2007). In the nervous system, S100A1 modulates innate fear and exploration of novel stimuli (Ackermann et al., 2006). In neuronal cells, S100A1 regulates cell proliferation, dendrite formation, intracellular calcium levels, microtubule stability, and amyloid precursor protein levels (Zimmer et al., 1995; Zimmer et al., 2005). In ganglion neurons, exogenous S100A1 increases sympathetic output by enhancing L-type calcium channel currents in a PKA-dependent manner (Hernández-Ochoa et al., 2009). In the heart, S100A1 regulation of the ryanodine receptor, SERCA pump and phospholamban alters Ca2+ handling; regulation of titin alters contractile performance; and regulation F1-ATPase alters mitochondrial energy metabolism (Rohde et al., 2010). In skeletal muscle, S100A1 interaction with the ryanodine receptor modulates excitation contraction coupling (Prosser et al., 2008; Wright et al, 2008). In endothelial cells, S100A1 moldulates calcium levels and nitric oxide production (Pleger et al., 2008). Additional S100A1 target proteins include the RAGE receptor, aldolase, annexin A6, the actin-capping protein CAPZA1, desmin, glial fibrillary acidic protein, the 43 kD gap junction protein (GJA1), heat shock proteins, immunophilins (CyP40 and FKBP52) phosphoglucomutase, glycogen phosphorylase kinase, tubulin, the calcyclin binding protein, and other S100s (S100A3, S100A4, S100B, S100P) (Wright et al, 2009b). Two structures of S100A1-target complexes have been characterized using NMR (Wright et al., 2008; Wright et al., 2009a). |
Homology | Species comparisons Human - Chimpanzee: 100% Human - Cow: 99% Human - Canine: 98% Human - Rat: 94% Human - Mouse: 94% Other S100 family members Human S100A1 - Human S100A4: 51% Human S100A1 - Human S100A5: 46% Human S100A1 - Human S100A7: 24% Human S100A1 - Human S100A10: 48% Human S100A1 - Human S100A13: 41% Human S100A1 - Human S100B: 60% Human S100A1 - Human S100P: 56% |
S100A1-deficient male mice exhibit increased exploratory activity and reduced anxiety-related responses. |
Ackermann GE, Marenholz I, Wolfer DP, Chan WY, Schafer B, Erne P, Heizmann CW. |
Biochim Biophys Acta. 2006 Nov;1763(11):1307-19. Epub 2006 Sep 6. |
PMID 17045663 |
|
Right ventricular upregulation of the Ca(2+) binding protein S100A1 in chronic pulmonary hypertension. |
Ehlermann P, Remppis A, Guddat O, Weimann J, Schnabel PA, Motsch J, Heizmann CW, Katus HA. |
Biochim Biophys Acta. 2000 Feb 21;1500(2):249-55. |
PMID 10657594 |
|
Augmentation of Cav1 channel current and action potential duration after uptake of S100A1 in sympathetic ganglion neurons. |
Hernandez-Ochoa EO, Prosser BL, Wright NT, Contreras M, Weber DJ, Schneider MF. |
Am J Physiol Cell Physiol. 2009 Oct;297(4):C955-70. Epub 2009 Aug 5. |
PMID 19657060 |
|
A panel of sputum-based genomic marker for early detection of lung cancer. |
Jiang F, Todd NW, Li R, Zhang H, Fang H, Stass SA. |
Cancer Prev Res (Phila). 2010 Dec;3(12):1571-8. Epub 2010 Sep 23. |
PMID 20864512 |
|
S100a0 (alpha alpha) protein: distribution in muscle tissues of various animals and purification from human pectoral muscle. |
Kato K, Kimura S, Haimoto H, Suzuki F. |
J Neurochem. 1986 May;46(5):1555-60. |
PMID 3514794 |
|
Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions. |
Keijser S, Missotten GS, Bonfrer JM, de Wolff-Rouendaal D, Jager MJ, de Keizer RJ. |
Br J Ophthalmol. 2006 Feb;90(2):213-7. |
PMID 16424536 |
|
Transcriptional regulation of S100A1 and expression during mouse heart development. |
Kiewitz R, Lyons GE, Schafer BW, Heizmann CW. |
Biochim Biophys Acta. 2000 Dec 20;1498(2-3):207-19. |
PMID 11108964 |
|
S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. |
Kraus C, Rohde D, Weidenhammer C, Qiu G, Pleger ST, Voelkers M, Boerries M, Remppis A, Katus HA, Most P. |
J Mol Cell Cardiol. 2009 Oct;47(4):445-55. Epub 2009 Jun 16. (REVIEW) |
PMID 19538970 |
|
S100A1 utilizes different mechanisms for interacting with calcium-dependent and calcium-independent target proteins. |
Landar A, Rustandi RR, Weber DJ, Zimmer DB. |
Biochemistry. 1998 Dec 15;37(50):17429-38. |
PMID 9860858 |
|
S100A1: a powerful marker to differentiate chromophobe renal cell carcinoma from renal oncocytoma. |
Li G, Barthelemy A, Feng G, Gentil-Perret A, Peoc'h M, Genin C, Tostain J. |
Histopathology. 2007 Apr;50(5):642-7. |
PMID 17394501 |
|
Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2). |
Most P, Boerries M, Eicher C, Schweda C, Ehlermann P, Pleger ST, Loeffler E, Koch WJ, Katus HA, Schoenenberger CA, Remppis A. |
J Biol Chem. 2003 Nov 28;278(48):48404-12. Epub 2003 Sep 6. |
PMID 12960148 |
|
Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. |
Nonaka D, Chiriboga L, Rubin BP. |
J Cutan Pathol. 2008 Nov;35(11):1014-9. Epub 2008 Jun 10. |
PMID 18547346 |
|
Endothelial S100A1 modulates vascular function via nitric oxide. |
Pleger ST, Harris DM, Shan C, Vinge LE, Chuprun JK, Berzins B, Pleger W, Druckman C, Volkers M, Heierhorst J, Oie E, Remppis A, Katus HA, Scalia R, Eckhart AD, Koch WJ, Most P. |
Circ Res. 2008 Apr 11;102(7):786-94. Epub 2008 Feb 21. |
PMID 18292599 |
|
Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. |
Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W, Gao E, Dasgupta A, Rengo G, Remppis A, Katus HA, Eckhart AD, Rabinowitz JE, Koch WJ. |
Circulation. 2007 May 15;115(19):2506-15. Epub 2007 Apr 30. |
PMID 17470693 |
|
S100A1 binds to the calmodulin-binding site of ryanodine receptor and modulates skeletal muscle excitation-contraction coupling. |
Prosser BL, Wright NT, Hernandez-Ochoa EO, Varney KM, Liu Y, Olojo RO, Zimmer DB, Weber DJ, Schneider MF. |
J Biol Chem. 2008 Feb 22;283(8):5046-57. Epub 2007 Dec 17. |
PMID 18089560 |
|
Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. |
Remppis A, Greten T, Schafer BW, Hunziker P, Erne P, Katus HA, Heizmann CW. |
Biochim Biophys Acta. 1996 Oct 11;1313(3):253-7. |
PMID 8898862 |
|
S100A1: a multifaceted therapeutic target in cardiovascular disease. |
Rohde D, Ritterhoff J, Voelkers M, Katus HA, Parker TG, Most P. |
J Cardiovasc Transl Res. 2010 Oct;3(5):525-37. Epub 2010 Jul 20. (REVIEW) |
PMID 20645037 |
|
S100A1 and S100B, transcriptional targets of SOX trio, inhibit terminal differentiation of chondrocytes. |
Saito T, Ikeda T, Nakamura K, Chung UI, Kawaguchi H. |
EMBO Rep. 2007 May;8(5):504-9. Epub 2007 Mar 30. |
PMID 17396138 |
|
Expression of the rat S100A1 gene in neurons, glia, and skeletal muscle. |
Song W, Zimmer DB. |
Brain Res. 1996 May 20;721(1-2):204-16. |
PMID 8793102 |
|
Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours. |
Sviatoha V, Tani E, Kleina R, Sperga M, Skoog L. |
Melanoma Res. 2010 Apr;20(2):118-25. |
PMID 20042890 |
|
Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma. |
Teratani T, Watanabe T, Kuwahara F, Kumagai H, Kobayashi S, Aoki U, Ishikawa A, Arai K, Nozawa R. |
Cancer Lett. 2002 Jan 10;175(1):71-7. |
PMID 11734338 |
|
S100A1: Structure, Function, and Therapeutic Potential. |
Wright NT, Cannon BR, Zimmer DB, Weber DJ. |
Curr Chem Biol. 2009b May 1;3(2):138-145. |
PMID 19890475 |
|
S100A1 and calmodulin compete for the same binding site on ryanodine receptor. |
Wright NT, Prosser BL, Varney KM, Zimmer DB, Schneider MF, Weber DJ. |
J Biol Chem. 2008 Sep 26;283(39):26676-83. Epub 2008 Jul 23. |
PMID 18650434 |
|
The three-dimensional solution structure of Ca(2+)-bound S100A1 as determined by NMR spectroscopy. |
Wright NT, Varney KM, Ellis KC, Markowitz J, Gitti RK, Zimmer DB, Weber DJ. |
J Mol Biol. 2005 Oct 21;353(2):410-26. |
PMID 16169012 |
|
Gene expression profiling of chromophobe renal cell carcinomas and renal oncocytomas by Affymetrix GeneChip using pooled and individual tumours. |
Yusenko MV, Zubakov D, Kovacs G. |
Int J Biol Sci. 2009 Jul 29;5(6):517-27. |
PMID 19680475 |
|
S100-mediated signal transduction in the nervous system and neurological diseases. |
Zimmer DB, Chaplin J, Baldwin A, Rast M. |
Cell Mol Biol (Noisy-le-grand). 2005 Sep 5;51(2):201-14. |
PMID 16171556 |
|
Isolation of a rat S100 alpha cDNA and distribution of its mRNA in rat tissues. |
Zimmer DB, Song W, Zimmer WE. |
Brain Res Bull. 1991 Aug;27(2):157-62. |
PMID 1742602 |
|
Tissue distribution of rat S100 alpha and S100 beta and S100-binding proteins. |
Zimmer DB, Van Eldik LJ. |
Am J Physiol. 1987 Mar;252(3 Pt 1):C285-9. |
PMID 3826357 |
|
The Calcium-Dependent Interaction of S100B with Its Protein Targets. |
Zimmer DB, Weber DJ. |
Cardiovasc Psychiatry Neurol. 2010;2010. pii: 728052. Epub 2010 Aug 17. |
PMID 20827422 |
|